Almirall (ALM) Stock Overview
Operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for ALM from our risk checks.
ALM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Almirall, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €11.34 |
| 52 Week High | €13.84 |
| 52 Week Low | €10.12 |
| Beta | 0.17 |
| 1 Month Change | 0.89% |
| 3 Month Change | 1.61% |
| 1 Year Change | 4.81% |
| 3 Year Change | 38.89% |
| 5 Year Change | n/a |
| Change since IPO | 28.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALM | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | 2.5% | 0.7% | 7.6% |
| 1Y | 4.8% | 10.3% | 36.3% |
Return vs Industry: ALM underperformed the Austrian Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: ALM underperformed the Austrian Market which returned 33.6% over the past year.
Price Volatility
| ALM volatility | |
|---|---|
| ALM Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in AT Market | 7.3% |
| 10% least volatile stocks in AT Market | 2.9% |
Stable Share Price: ALM has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: ALM's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1943 | 2,108 | Carlos Gallardo Piqué | www.almirall.com |
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal system, nervous system, respiratory system, systemic hormonal preparations. It also develops tirbanibulin for actinic keratosis, and tildrakizumab for psoriatic arthritis under the registration phase, as well as lebrikizumab for atopic dermatitis pediatric in phase 2; Anti-IL-1RAP mAb for hidradenitis suppurativa, anti-IL-1RAP mAb for inflammatory skin disease, Anti-IL-21 mAb for hidradenitis suppurativa, IL-2muFc for alopecia areata, IL-2muFc for atopic dermatitis, and IL-2muFc for inflammatory skin disease in phase 2; readthrough inducer for rare dermatology in phase 1; and anti-IL-13/OX40L BsAb for atopic dermatitis, SMOL oral for Th2-driven diseases, and mRNA/LNP for non-melanoma skin cancer in preclinical stage.
Almirall, S.A. Fundamentals Summary
| ALM fundamental statistics | |
|---|---|
| Market cap | €2.43b |
| Earnings (TTM) | €39.85m |
| Revenue (TTM) | €1.12b |
Is ALM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALM income statement (TTM) | |
|---|---|
| Revenue | €1.12b |
| Cost of Revenue | €270.23m |
| Gross Profit | €850.60m |
| Other Expenses | €810.75m |
| Earnings | €39.85m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 24, 2026
| Earnings per share (EPS) | 0.19 |
| Gross Margin | 75.89% |
| Net Profit Margin | 3.56% |
| Debt/Equity Ratio | 18.9% |
How did ALM perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/17 13:47 |
| End of Day Share Price | 2026/06/17 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Almirall, S.A. is covered by 27 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Banco de Sabadell. S.A. |
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |